1. Home
  2. CRDF vs MTA Comparison

CRDF vs MTA Comparison

Compare CRDF & MTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDF
  • MTA
  • Stock Information
  • Founded
  • CRDF 1999
  • MTA 1983
  • Country
  • CRDF United States
  • MTA Canada
  • Employees
  • CRDF N/A
  • MTA N/A
  • Industry
  • CRDF Biotechnology: Biological Products (No Diagnostic Substances)
  • MTA
  • Sector
  • CRDF Health Care
  • MTA
  • Exchange
  • CRDF Nasdaq
  • MTA Nasdaq
  • Market Cap
  • CRDF 144.4M
  • MTA 506.2M
  • IPO Year
  • CRDF N/A
  • MTA N/A
  • Fundamental
  • Price
  • CRDF $2.04
  • MTA $5.59
  • Analyst Decision
  • CRDF Strong Buy
  • MTA Hold
  • Analyst Count
  • CRDF 5
  • MTA 1
  • Target Price
  • CRDF $11.10
  • MTA $4.50
  • AVG Volume (30 Days)
  • CRDF 1.1M
  • MTA 890.7K
  • Earning Date
  • CRDF 11-06-2025
  • MTA 11-13-2025
  • Dividend Yield
  • CRDF N/A
  • MTA N/A
  • EPS Growth
  • CRDF N/A
  • MTA N/A
  • EPS
  • CRDF N/A
  • MTA N/A
  • Revenue
  • CRDF $545,000.00
  • MTA $8,167,999.00
  • Revenue This Year
  • CRDF N/A
  • MTA $120.74
  • Revenue Next Year
  • CRDF N/A
  • MTA $54.89
  • P/E Ratio
  • CRDF N/A
  • MTA N/A
  • Revenue Growth
  • CRDF N/A
  • MTA 70.70
  • 52 Week Low
  • CRDF $1.90
  • MTA $2.45
  • 52 Week High
  • CRDF $5.64
  • MTA $5.94
  • Technical
  • Relative Strength Index (RSI)
  • CRDF 36.16
  • MTA 65.73
  • Support Level
  • CRDF $2.03
  • MTA $5.45
  • Resistance Level
  • CRDF $2.27
  • MTA $5.94
  • Average True Range (ATR)
  • CRDF 0.12
  • MTA 0.31
  • MACD
  • CRDF 0.04
  • MTA 0.02
  • Stochastic Oscillator
  • CRDF 37.84
  • MTA 75.52

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.

Share on Social Networks: